Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study

Julien Lazarovici, Sandy Amorim, Krimo Bouabdallah, Marguerite Fournier, Stéphanie Guidez, Lysiane Molina, Franck Morschhauser, Baptiste Delapierre, Thomas Gastinne, Kamel Laribi, Vincent Launay, Bohrane Slama, Nawel Belmecheri, René-Olivier Casasnovas, Anne Corby, Eric Durot, Pierre Feugier, Emmanuelle Nicolas-Virelizie, David Sibon, Alina Berriolo-Riedinger, Véronique Edeline, Thierry Vander Borght, Diane Damotte, Alexandra Traverse-Glehen, Vincent Ribrag, Marc André

Open source

DOI: 10.3324/haematol.2025.300166
Published: 2026-05-28
Container: Haematologica
Publisher: Ferrata Storti Foundation (Haematologica)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2025.300166,
  title = {Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study},
  author = {Julien Lazarovici and Sandy Amorim and Krimo Bouabdallah and Marguerite Fournier and Stéphanie Guidez and Lysiane Molina and Franck Morschhauser and Baptiste Delapierre and Thomas Gastinne and Kamel Laribi and Vincent Launay and Bohrane Slama and Nawel Belmecheri and René-Olivier Casasnovas and Anne Corby and Eric Durot and Pierre Feugier and Emmanuelle Nicolas-Virelizie and David Sibon and Alina Berriolo-Riedinger and Véronique Edeline and Thierry Vander Borght and Diane Damotte and Alexandra Traverse-Glehen and Vincent Ribrag and Marc André},
  year = {2026},
  journal = {Haematologica},
  doi = {10.3324/haematol.2025.300166},
  url = {https://doi.org/10.3324/haematol.2025.300166}
}

RIS

TY  - JOUR
TI  - Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study
AU  - Julien Lazarovici
AU  - Sandy Amorim
AU  - Krimo Bouabdallah
AU  - Marguerite Fournier
AU  - Stéphanie Guidez
AU  - Lysiane Molina
AU  - Franck Morschhauser
AU  - Baptiste Delapierre
AU  - Thomas Gastinne
AU  - Kamel Laribi
AU  - Vincent Launay
AU  - Bohrane Slama
AU  - Nawel Belmecheri
AU  - René-Olivier Casasnovas
AU  - Anne Corby
AU  - Eric Durot
AU  - Pierre Feugier
AU  - Emmanuelle Nicolas-Virelizie
AU  - David Sibon
AU  - Alina Berriolo-Riedinger
AU  - Véronique Edeline
AU  - Thierry Vander Borght
AU  - Diane Damotte
AU  - Alexandra Traverse-Glehen
AU  - Vincent Ribrag
AU  - Marc André
PY  - 2026
JO  - Haematologica
DO  - 10.3324/haematol.2025.300166
UR  - https://doi.org/10.3324/haematol.2025.300166
ER  -

APA

Lazarovici, J., Amorim, S., Bouabdallah, K., Fournier, M., Guidez, S., Molina, L., Morschhauser, F., Delapierre, B., Gastinne, T., Laribi, K., Launay, V., Slama, B., Belmecheri, N., Casasnovas, R., Corby, A., Durot, E., Feugier, P., Nicolas-Virelizie, E., Sibon, D., Berriolo-Riedinger, A., Edeline, V., Borght, T. V., Damotte, D., Traverse-Glehen, A., Ribrag, V., & André, M. (2026). Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study. Haematologica. https://doi.org/10.3324/haematol.2025.300166

Source records

crossref · retrieved 2026-09-27T10:30:41.958Z